EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of the planned discussion with the FDA leading to the confirmation to file a New Drug ...

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by ne ...

Summary of Praxis Precision Medicines Fireside Chat Company Overview - **Company**: Praxis Precision Medicines (NasdaqGS:PRAX) - **Focus**: Development of treatments for epilepsy, specifically targeting SCN2A and SCN8A disorders Key Points and Arguments 1. Relutrigine Development - **Overlooked Asset**: Relutrigine is considered significantly undervalued by the market, with potential to justify the company's valuation [2][19] - **Accelerated Pathway**: The company is exploring an accelerated pathway for Relutrigine, with Breakthrough Therapy Designation from the FDA [2][4] - **Cohort Design**: The design of the Evolve study has been robust, showing strong effects and leading to FDA engagement for potential acceleration [5][6][24] - **Interim Analysis**: The interim analysis is designed to maximize the chance of success, allowing for a quicker NDA submission [8][25] 2. Market Opportunity - **Multi-Billion Dollar Potential**: The market opportunity for SCN2A and SCN8A is projected to be multi-billion dollars, with accelerated timelines for approval [9][12][26] - **Pediatric Review Voucher**: The potential for a pediatric review voucher is acknowledged as a non-dilutive capital opportunity, although its importance is debated [8][26] 3. Emerald Study - **Emerald Population**: The strategy for the Emerald study is to finalize it in conjunction with the Evolve study, which is expected to accelerate the overall approval timeline [12][28] - **Enrollment Timeline**: Enrollment for the Emerald study is on track, with expectations to file for SNDA by early 2027 [59] 4. Statistical Analysis - **P-Value Significance**: The updated data from the first cohort showed a small P-value, indicating strong statistical significance in seizure reduction [30][34] - **ANCOVA Model**: The analysis will utilize an ANCOVA model to account for baseline seizure counts and other covariates [36][34] 5. Competitive Landscape - **Faster Enrollment**: Praxis is experiencing faster enrollment compared to competitors, attributed to targeted recruitment strategies and understanding patient needs [61][64] - **Commercial Launch Preparation**: Insights gained during clinical trials are expected to enhance the commercial launch strategy [66] 6. Pricing Strategy - **Pricing Philosophy**: The company plans to price Relutrigine based on its initial indication (SCN2A and SCN8A) rather than future broader indications [69][70] - **Market Justification**: The potential market for SCN2A is estimated to be between $500 million to $1 billion, with a clear rationale for pricing in the rare disease space [71][72] 7. Ulixacaltamide Update - **Pre-NDA Meeting**: The upcoming pre-NDA meeting is seen as a critical step in confirming the appropriateness of the filing package [75][78] - **Breakthrough Designation Consideration**: The company is open to applying for breakthrough designation if it aligns with their strategic goals [79] Additional Important Insights - **Patient Need**: There is a strong emphasis on the unmet need for effective treatments in the targeted patient populations, which drives the urgency for market entry [45][57] - **Regulatory Engagement**: Continuous dialogue with the FDA is highlighted as essential for navigating the approval process effectively [24][40] This summary encapsulates the critical discussions and insights from the Praxis Precision Medicines fireside chat, focusing on the development of Relutrigine and the broader strategic direction of the company.

Core Insights - Praxis Precision Medicines is advancing its clinical programs in developmental and epileptic encephalopathies (DEEs), highlighting significant opportunities in this field [2][5] - The company is focusing on two main therapeutic candidates: Relutrigine and Elsunersen, both showing promising results in clinical studies [5][8] Relutrigine - Relutrigine has demonstrated a mean seizure reduction of approximately 90% from baseline after 11 months of patient dosing in the EMBOLD study [5] - The EMBOLD study is expected to provide topline results by the first half of 2026, with a registrational study (EMERALD) planned to start in mid-2025, targeting a US market potential of at least $3 billion [5][7] - Relutrigine is a first-in-class small molecule that selectively inhibits persistent sodium current, showing dose-dependent inhibition of seizures in various DEE mouse models [7] Elsunersen - Elsunersen is an antisense oligonucleotide (ASO) targeting SCN2A gain-of-function mutations, with significant seizure reduction observed in clinical studies [8] - The EMBRAVE3 trial is set to enroll patients aged 2-18, with plans for treatment initiation from birth, reflecting the early onset of SCN2A DEE [5][8] - The global market potential for Elsunersen is estimated at $1 billion, based on a target population of approximately 5,000 patients [5] Pipeline and Future Developments - Praxis plans to nominate a development candidate for its early-stage ASO program PRAX-100, targeting SCN2A loss-of-function mutations, by mid-2025 [11] - The company is also on track to nominate development candidates for PRAX-080 and PRAX-090 by the end of 2025, focusing on PCDH19 and SYNGAP1 mutations respectively [11] - The company is leveraging its proprietary platforms, Cerebrum™ and Solidus™, to develop therapies for CNS disorders [9]